Is Blinatumomab Now Standard of Care Consolidation for Patients With ALL?

H&O What is blinatumomab and how does it work in treating acute lymphocytic leukemia (ALL)? SL Blinatumomab (Blincyto, Amgen), which is classified as a bispecific antibody, […]

Quizartinib, the Next FLT3 Inhibitor

H&O What are FMS-like tyrosine kinase 3 (FLT3) inhibitors, and how have they affected the treatment of patients with acute myeloid leukemia (AML)? JC FLT3 mutations […]

Momelotinib, the Next JAK2 Inhibitor?

H&O What is momelotinib and how does it work? LM Momelotinib is a selective inhibitor of Janus kinase 1 (JAK1), JAK2, and activin A receptor type […]

Zandelisib and B-Cell Lymphomas

H&O How does zandelisib work? AZ Zandelisib is a phosphoinositide 3-kinase delta (PI3K-δ) inhibitor with a long half-life. PI3K comes in multiple isoforms, including alpha, beta, […]

Noncovalent BTK Inhibitors in B-Cell Lymphoma

H&O What are the limitations of standard (covalent) BTK inhibitors in B-cell malignancies? CC The 2 major limitations of covalent Bruton’s tyrosine kinase (BTK) inhibitors are […]

Optimizing the Benefits of BCMA-Targeted CAR T-Cell Therapy in Multiple Myeloma

H&O Why is the B-cell maturation antigen (BCMA) a good target for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma? SL BCMA is an important […]

Targeting the Microbiome to Improve Outcomes in Stem Cell Transplant

H&O What are the characteristics of a healthy microbiome? DP A healthy microbiome is dynamic and diverse. It consists of many different types of commensal bacteria—predominantly […]

Key Points From the SHINE Trial in Mantle Cell Lymphoma

H&O Could you provide some background on mantle cell lymphoma? JT Mantle cell lymphoma is an uncommon type of lymphoma. It represents approximately 6% of non-Hodgkin […]

Advances in the Classification and Management of Patients With T-Cell Lymphoma

H&O What are the most common types of T-cell lymphoma? LP T-cell lymphoma is a heterogeneous group of disorders that encompass many subtypes. T-cell lymphomas that […]

Hyper-CVAD–Based Regimens in Adult Patients With Acute Lymphoblastic Leukemia

H&O How was the hyper-CVAD regimen originally used? EJ The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen was developed by Kantarjian and colleagues at MD […]

The Future Role of Bispecific Antibodies in Lymphoma

H&O What is the mechanism of action of bispecific antibodies? JA Bispecific antibodies aim to harness the power of the immune system. These treatments are monoclonal […]

New Approaches to T-Cell Acute Lymphoblastic Leukemia

H&O How common is T-cell acute lymphoblastic leukemia (T-ALL)? DT ALL is uncommon, accounting for approximately 6700 new diagnoses per year in the United States. Between […]

Insights Into the Management of Patients With Primary Central Nervous System Lymphoma

H&O What is the definition of primary central nervous system (CNS) lymphoma ? CF Primary CNS lymphoma is referred to as primary diffuse large B-cell lymphoma […]

Evolving Management of Patients With Double-Hit Lymphoma

H&O What is the definition of double-hit lymphoma? AL Double-hit lymphoma is an aggressive B-cell lymphoma with MYC translocation and a BCL2 and/or BCL6 translocation. The […]

Recent Data for Acalabrutinib in Chronic Lymphocytic Leukemia

H&O What type of drug is acalabrutinib? PG Acalabrutinib (Calquence, AstraZeneca) is a so-called next-generation Bruton’s tyrosine kinase (BTK) inhibitor. The first-generation BTK inhibitor, ibrutinib (Imbruvica, […]

Umbralisib and Ublituximab: An Upcoming Regimen for Chronic Lymphocytic Leukemia

H&O What types of drugs are umbralisib and ublituximab? JG Umbralisib (Ukoniq, TG Therapeutics) is a phosphoinositide 3 (PI3) kinase delta inhibitor. Umbralisib is approved for […]

Zanubrutinib: A Novel BTK Inhibitor in Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

H&O What type of drug is zanubrutinib? CT Zanubrutinib, also known as BGB-3111, is a next-generation Bruton’s tyrosine kinase (BTK) inhibitor. It inhibits BTK irreversibly […]

Guideline Recommendations for the Prophylaxis of Invasive Aspergillosis in AML

Clinical Advances in Hematology & Oncology Volume 14, Issue 11, November 2016 Eunice S. Wang, MD Chief, Leukemia Service Professor of Oncology, Department of Medicine Roswell […]

Consolidation Therapy After Autologous Stem Cell Transplant in Relapsed/Refractory Hodgkin Lymphoma

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Craig H. Moskowitz, MD Steven A. Greenberg Chair in Lymphoma Research Clinical Director, Division […]

Are We Ready for Precision Medicine in Acute Myeloid Leukemia?

Clinical Advances in Hematology & Oncology Volume 14, Issue 8, August 2016 Advances in LLM Gail J. Roboz, MD Professor of Medicine Weill Cornell Medicine […]